Notícias Immunome Inc - IMNM | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Immunome Inc (IMNM)
Immunome Inc (IMNM) Notícias

Immunome Inc (IMNM)

12,60

1,01

( 8,71% )

Atualizado: 15:29:53

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K - Current report

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições